Shree Ganesh Remedies Faces Valuation Shift Amid Mixed Financial Performance Indicators
Shree Ganesh Remedies, a small-cap pharmaceutical company, has experienced a recent adjustment in its valuation grade. Despite a 21.36% return over the past year, key financial indicators showed declines, including significant drops in profit before and after tax. However, the company maintains a strong debt management profile and healthy long-term growth metrics.
Shree Ganesh Remedies, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in evaluation, reflecting a shift in its valuation grade. The company's valuation metrics indicate a PE ratio of 34.68 and a price-to-book value of 7.58, positioning it within a higher valuation spectrum compared to its peers. Despite a notable return of 21.36% over the past year, the company reported a decline in key financial indicators for the quarter ending March 2025. Specifically, profit before tax (PBT) fell by 56.60%, while profit after tax (PAT) decreased by 47.7%, with net sales reaching a low of Rs 24.43 crore.
On a positive note, Shree Ganesh Remedies has demonstrated a strong capacity to manage debt, evidenced by a low debt-to-EBITDA ratio of 0.46 times. Additionally, the company has shown healthy long-term growth, with net sales increasing at an annual rate of 25.29% and operating profit rising by 38.49%.
Overall, the recent revision in its score reflects the complexities of its financial landscape, balancing strong growth potential against recent performance challenges.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
